Jianguo Zhi
Overview
Explore the profile of Jianguo Zhi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
739
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zhi J, Zhai S, Boldrin M
Clin Pharmacol Drug Dev
. 2016 Jul;
6(3):258-265.
PMID: 27364955
To determine the effect of piragliatin on the QTcS (QT-corrected study-specific) interval, a double-blind, double-dummy, placebo-controlled, active-comparator, 4-period, 4-treatment, 4-sequence randomized crossover trial was performed in 42 patients with type...
12.
Glenn K, Yu L, Reddy M, Fretland A, Parrott N, Hussain S, et al.
Xenobiotica
. 2015 Nov;
46(8):667-76.
PMID: 26586447
1. Idasanutlin (RG7388) is a potent p53-MDM2 antagonist currently in clinical development for treatment of cancer. The purpose of the present studies was to investigate the cause of marked decrease...
13.
Andreeff M, Kelly K, Yee K, Assouline S, Strair R, Popplewell L, et al.
Clin Cancer Res
. 2015 Oct;
22(4):868-76.
PMID: 26459177
Purpose: RG7112 is a small-molecule MDM2 antagonist. MDM2 is a negative regulator of the tumor suppressor p53 and frequently overexpressed in leukemias. Thus, a phase I study of RG7112 in...
14.
Georgy A, Zhai S, Liang Z, Boldrin M, Zhi J
J Clin Pharmacol
. 2015 Sep;
56(6):675-82.
PMID: 26381165
To evaluate the potential pharmacokinetic (PK) and pharmacodynamic (PD, glucose-lowering effect) interaction between simvastatin and piragliatin, both CYP3A substrates, 30 patients with type 2 diabetes mellitus participated in this open-label,...
15.
Zhi J, Zhai S, Georgy A, Liang Z, Boldrin M
J Clin Pharmacol
. 2015 Aug;
56(5):548-54.
PMID: 26272330
Piragliatin is a CYP3A substrate; its inactive metabolite M4, formed through cytosolic reductase, is reversibly metabolized back to piragliatin through CYP3A. The impact of concomitant CYP3A modifiers thus cannot be...
16.
Patnaik A, Tolcher A, Beeram M, Nemunaitis J, Weiss G, Bhalla K, et al.
Cancer Chemother Pharmacol
. 2015 Jul;
76(3):587-95.
PMID: 26210682
Purpose: RG7112, the first selective small-molecule MDM2 antagonist in clinical testing, is a non-genotoxic oral p53 activator. To optimize its dose and schedule, a number of clinical pharmacology characteristics were...
17.
Zhi J, Zhai S
J Clin Pharmacol
. 2015 Jul;
56(2):231-8.
PMID: 26183686
To assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of piragliatin, a double-blind, randomized, placebo-controlled, multiple-ascending-doses study was conducted in patients with type 2 diabetes mellitus (T2D). Fifty-nine T2D...
18.
Ray-Coquard I, Blay J, Italiano A, Cesne A, Penel N, Zhi J, et al.
Lancet Oncol
. 2012 Oct;
13(11):1133-40.
PMID: 23084521
Background: We report a proof-of-mechanism study of RG7112, a small-molecule MDM2 antagonist, in patients with chemotherapy-naive primary or relapsed well-differentiated or dedifferentiated MDM2-amplified liposarcoma who were eligible for resection. Methods:...
19.
Li J, Zhi J, Wenger M, Valente N, Dmoszynska A, Robak T, et al.
J Clin Pharmacol
. 2012 Jan;
52(12):1918-26.
PMID: 22235140
This retrospective analysis characterizes rituximab population pharmacokinetics in combination with fludarabine and cyclophosphamide and its effect on fludarabine and cyclophosphamide disposition in chronic lymphocytic leukemia (CLL) patients. Rituximab concentration data...
20.